Sentcell
Revolutionizing Human Rejuvenation And Anti-Ageing

Is it possible to reverse the ageing clock in humans and extend the lifespan? This million-dollar question may finally have an answer.

The lifespan of a CD4+ T cell, which is at the pinnacle of the ageing clock, holds the key to human well-being. Reversing ageing and curing age-related diseases may now be possible by focusing on a single cell. T cell rejuvenating therapies that deliver immune protection over a lifetime offer boundless possibilities to respond to unmet medical needs.

Sentcell is taking charge of this revolution in human longevity by delaying ageing and improving lifespan with remarkably promising human rejuvenation and anti-ageing therapies.

The first company to implement fundamental medicine, Sentcell is developing first-class pharmaceutical classes to target pillars of ageing through selective T cell rejuvenation. No viable T cell rejuvenating therapies exist in the medical field, and the team is committed to bridge this gap with its premium platform.

More than 15 years of single-topic research and investigation of fundamental biology have culminated in Sentcell’s momentous discovery of the Sestrin MAP kinase activation complex (sMAC), as a multi-druggable longevity target in 2017. A rational design focused on a single pathway characterizes its rejuvenation therapies.

Setting Sentcell ahead of the competition is its approach based on unique and previously unknown anti-ageing biology to design innovative compounds. They modulate the immune state, particularly in T Cells, to produce broader systemic effects.

"We focus all our efforts on helping humanity break the chains of ageing and disease," says Dr. Alessio Lanna, CEO and Chairman of Sentcell.

Disruptive Discovery Extending Health Span

sMACs are large macromolecular complexes formed during the ageing of T cells and possibly other cell types. This activated complex is present mostly in the senescent, dysfunctional T cells, or their progenitors, formed upon a failed round of telomere transfer. sMAC leads to deterioration of the immune response, with the consequent onset of infections, cancers and, eventually, death.

Most companies base their longevity research on molecules, particularly mammalian target of rapamycin (mTOR) that are not even present in aged immune systems, rendering their targeting impossible. Sentcell turns sMAC into an advantage instead. It uses sMAC to chart a holistic approach to slow down or reverse ageing. The discovery is highly potent, as currently there are no drugs to modulate the complex to activate or block it.

Through an academic lens and a business mindset, Sentcell is engaged in proving that when aspects of the immune response are modulated by targeting specific points of the sMAC complex and the associated telomere transfer reaction, the lifespan of the CD4 T cell can be extended. Acting on this complex makes it possible to achieve highly important effects for various pathologies. All Sentcell drugs act inside T cells, specifically by interacting with sMAC.

The team delves deep into the composition of an immune repertoire in elders suffering from accelerated ageing, chronic infections, autoimmune disorders, and other problems. All products in the Sentcell pipeline define newer pharmaceutical classes.

Bolstering Human Immune Response

Sentcell’s lead compound, currently under the latest Investigational New Drug (IND) stages in preparation for clinical trials, is called Disruptors Of sMAC (DOS), a new immune patent-pending rejuvenating class. It gives a clear advantage over checkpoint immunotherapy, which delivers temporary results targeting exhausted (non senescent) T cells. DOS can destroy sMAC through ubiquitin-dependent proteasome degradation to facilitate long-term rejuvenation of senescent cells. In preclinical studies, it is proved that a single injection of DOS extends an animal’s lifespan up to the equivalent of 120 human years. Its application is also against long-term conditions that specifically affect T-cells, such as HIV.

DOS-based approach not only rejuvenates the T cells but the entire organism, and when combined with vaccination, can provide a stronger immune response that allows for long-lasting, quality protection. Sentcell has proved that DOS, when combined with clinically approved influenza and COVID-19 vaccinations, is a game changer in rejuvenating the immune system. It aims to partner with investors and pharmaceutical companies to add the component to more vaccine formulations. It’s a flexible technology that can be employed in a variety of innovative schemes.

While the DOS excels in rejuvenation, Sentcell uses its novel compound, Negators Of sMAC (NOS), to prevent ageing by impeding sMAC formation. Unlike DOS, NOS is administered at a younger age when senescent has not yet manifested. It serves in pathologies such as mitochondrial diseases and provides reverse agonist activity against an undisclosed sMAC-generating pathway, leading to life span extension.

“Rejuvenation and anti-ageing cannot be used interchangeably, and pathways for the two purposes are exclusive. At Sentcell, we understand it well and leverage our platform in the right direction to tackle the challenges," says Lanna.

However, the use of the DOS and NOS can be combined. Once a person is rejuvenated using DOS, the NOS application can sustain the rejuvenation results.

Molecules that promote sMAC formation, like patent-pending Mobiliser Of sMAC (MOS), have also been developed. The reason for sMAC stimulation is that before the senescence of T cells, there is a massive expansion of lymphocytes, which effectively control aggressive cancers and other life-threatening conditions. Under certain conditions, the presence of the complex can be exploited, such as in autoimmune disorders or cases that require rampant immune activation, such as sepsis or untreatable cancers. Patients often have a matter of weeks or months to survive against cancers refractory to chemotherapy, radiotherapy, or immunotherapy, and 48 hours in case of sepsis and infections. In these situations, senescence is an acceptable price to pay, and MOS can be the emergency medicine that stimulates an aggressive immune reaction against cancers or infected tissues to save people's lives.

Equally impressive are Sentcell LOS and COS, both in the early stages of development. They inhibit or activate the sMAC and can be used for neurodegenerative diseases such as Alzheimer’s and conditions like Schizophrenia conditions whereby the link between the immune system particularly T cells and neuronal function has begun to appear.
With an innovation-led culture at its core, Sentcell has ignited the light of new hope for humanity with another phenomenal discovery of a new anti-ageing intervention, telomere transfer. The seed of this discovery was sown seven years ago, and it fructified when the team uncovered the pathway that proved to be 30 times more powerful and faster than Telomerase, a Nobel Prize winning discovery and enzyme that replenishes the ends of chromosomes containing telomeres as they typically shorten with cell division. Telomere transfer entails transferring telomeres from antigen-presenting cells via vesicles to T cells. The transferred telomeres fuse and merge with the chromosome ends to elongate it inside the T cell. This way, the T cells are fully protected from senescence and can live forever, in stem state, challenging the status quo.
Making a Mark in the Longevity Arena

The team begins its research to treat diseases by working on peripheral T cells in human blood. It investigates the pathways, signaling, and biochemistry inside these cells from donors. Once human sMAC is modulated in vitro, the same pathways are interrogated in animals. It shows that the response can be modulated in a human cell in vitro or in an animal in vivo. This sets the stage for the first human dosing planned later this year.

“We do not depend on in silico or Artificial Intelligence data but follow the authentic old fashion proteins-based approach to prove the efficacy of our compounds,” says Lanna.

From the discovery of sMAC to going all out to reach the Phase 1 clinical trial cost-effectively, Sentcell’s remarkable tale of success is a testament to its quest for excellence. Having successfully completed the seed and series A funding, the company is geared for the next funding round to advance in clinical trials and release its invention for commercial use.

Sentcell’s journey over the years has been nothing short of inspirational, pushing the boundaries of therapeutic advancements to a new era of human longevity.